Study summary · research use only
Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This laboratory study (species not specified) examined how oncolytic adenovirus (ADV) affects tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) in the tumor microenvironment (TME), and whether thymosin alpha 1 (Tα1) modifies this response. The authors report that type V adenovirus induced polarization of TAMs toward an M2 phenotype and increased Treg infiltration in the TME. Tα1 was reported to reprogram "M2-like" TAMs toward an antitumoral phenotype, and a construct combining ADV and Tα1 (ADVTα1) was described. Both exogenously supplied and adenovirus-produced Tα1 were reported to be associated with TAM reprogramming and increased antitumor activity of ADV via CD8+ T cells.
Abstract
Although oncolytic adenoviruses are widely studied for their direct oncolytic activity and immunomodulatory role in cancer immunotherapy, the immunosuppressive feedback loop induced by oncolytic adenoviruses remains to be studied. Here, we demonstrate that type V adenovirus (ADV) induces the polarization of tumor-associated macrophages (TAMs) to the M2 phenotype and increases the infiltration of regulatory T cells (Tregs) in the tumor microenvironment (TME). By selectively compensating for these deficiencies, thymosin alpha 1 (Tα1) reprograms "M2-like" TAMs toward an antitumoral phenotype, thereby reprogramming the TME into a state more beneficial for antitumor immunity. Moreover, ADVTα1 is constructed by harnessing the merits of all the components for the aforementioned combinatorial therapy. Both exogenously supplied and adenovirus-produced Tα1 orchestrate TAM reprogramming and enhance the antitumor efficacy of ADV via CD8+ T cells, showing promising prospects for clinical translation. Our findings provide inspiration for improving oncolytic adenovirus combination therapy and designing oncolytic engineered adenoviruses.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.